Europe Biobanking Market Report and Forecast 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Europe Biobanking Market Overview 
    3.1    Europe Biobanking Market Historical Value (2017-2023) 
    3.2    Europe Biobanking Market Forecast Value (2024-2032)
4    Europe  Biobanking Market Landscape*
4.1    Europe Biobanking: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Europe Biobanking: Product Landscape
        4.2.1    Analysis by Product and Service    
        4.2.2    Analysis by Application
5    Europe Biobanking Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Europe Biobanking Market Segmentation (2017-2032)
    6.1    Europe Biobanking Market (2017-2032) by Product and Service
        6.1.1    Market Overview
        6.1.2    Equipment
        6.1.3    Consumables
        6.1.4    Service
        6.1.5    Software
    6.2    Europe Biobanking Market (2017-2032) by Application
        6.2.1    Market Overview
        6.2.2    Regenerative Medicine
        6.2.3    Life Science Research
        6.2.4    Clinical Research
    6.3    Europe Biobanking Market (2017-2032) by Sample Type
        6.3.1    Market Overview
        6.3.2    Blood Tissue
        6.3.3    Nucleic Acids
        6.3.4    Cell Lines
    6.4    Europe Biobanking Market (2017-2032) by End User
        6.4.1    Market Overview
        6.4.2    Academic Institutions
        6.4.3    Pharma and Biotech Companies
    6.5    Europe Biobanking Market (2017-2032) by Country
        6.5.1    Market Overview
        6.5.2    United Kingdom
        6.5.3    Germany
        6.5.4    France
        6.5.5    Italy
7    United Kingdom Biobanking Market (2017-2032)
    7.1    United Kingdom Biobanking Market (2017-2032) by Product and Service
        7.1.1    Market Overview    
        7.1.2    Equipment
        7.1.3    Consumables
        7.1.4    Service
        7.1.5    Software
    7.2    United Kingdom Biobanking Market (2017-2032) by Application
        7.2.1    Market Overview
        7.2.2    Regenerative Medicine
        7.2.3    Life Science Research
        7.2.4    Clinical Research 
    7.3    United Kingdom Biobanking Market (2017-2032) by Sample Type
        7.3.1    Market Overview
        7.3.2    Blood Tissue
        7.3.3    Nucleic Acids
        7.3.4    Cell Lines 
    7.4    United Kingdom Biobanking Market (2017-2032) by End User
        7.4.1    Market Overview
        7.4.2    Academic Institutions
        7.4.3    Pharma and Biotech Companies
8    Germany Biobanking Market (2017-2032)
    8.1    Germany Biobanking Market (2017-2032) by Product and Service
        8.1.1    Market Overview    
        8.1.2    Equipment
        8.1.3    Consumables
        8.1.4    Service
        8.1.5    Software
    8.2    Germany Biobanking Market (2017-2032) by Application
        8.2.1    Market Overview
        8.2.2    Regenerative Medicine
        8.2.3    Life Science Research
        8.2.4    Clinical Research
    8.3    Germany Biobanking Market (2017-2032) by Sample Type
        8.3.1    Market Overview
        8.3.2    Blood Tissue
        8.3.3    Nucleic Acids
        8.3.4    Cell Lines 
    8.4    Germany Biobanking Market (2017-2032) by End User
        8.4.1    Market Overview
        8.4.2    Academic Institutions
        8.4.3    Pharma and Biotech Companies
9    France  Biobanking Market (2017-2032)
    9.1    France Biobanking Market (2017-2032) by Product and Service
        9.1.1    Market Overview    
        9.1.2    Equipment
        9.1.3    Consumables
        9.1.4    Service
        9.1.5    Software 
    9.2    France Biobanking Market (2017-2032) by Application
        9.2.1    Market Overview
        9.2.2    Regenerative Medicine
        9.2.3    Life Science Research
        9.2.4    Clinical Research
    9.3    France Biobanking Market (2017-2032) by Sample Type
        9.3.1    Market Overview
        9.3.2    Blood Tissue
        9.3.3    Nucleic Acids
        9.3.4    Cell Lines 
    9.4    France Biobanking Market (2017-2032) by End User
        9.4.1    Market Overview
        9.4.2    Academic Institutions
        9.4.3    Pharma and Biotech Companies
10    Italy Biobanking Market (2017-2032)
    10.1     Italy Biobanking Market (2017-2032) by Product and Service
        10.1.1    Market Overview    
        10.1.2    Equipment
        10.1.3    Consumables
        10.1.4    Service
        10.1.5    Software 
    10.2     Italy Biobanking Market (2017-2032) by Application
        10.2.1    Market Overview
        10.2.2    Regenerative Medicine
        10.2.3    Life Science Research
        10.2.4    Clinical Research
    10.3     Italy Biobanking Market (2017-2032) by Sample Type
        10.3.1    Market Overview
        10.3.2    Blood Tissue
        10.3.3    Nucleic Acids
        10.3.4    Cell Lines
    10.4     Italy Biobanking Market (2017-2032) by End User
        10.4.1    Market Overview
        10.4.2    Academic Institutions
        10.4.3    Pharma and Biotech Companies 
11    Regulatory Framework
12    Patent Analysis
    12.1     Analysis by Type of Patent
    12.2     Analysis by Publication Year
    12.3     Analysis by Issuing Authority
    12.4     Analysis by Patent Age
    12.5     Analysis by CPC Analysis
    12.6     Analysis by Patent Valuation 
    12.7     Analysis by Key Players
13    Grants Analysis
    13.1     Analysis by Year
    13.2     Analysis by Amount Awarded
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Grant Application
    13.5     Analysis by Funding Institute
    13.6     Analysis by Departments
    13.7     Analysis by Recipient Organization 
14    Funding and Investment Analysis
    14.1     Analysis by Funding Instances
    14.2     Analysis by Type of Funding
    14.3     Analysis by Funding Amount
    14.4     Analysis by Leading Players
    14.5     Analysis by Leading Investors
    14.6     Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1     Analysis by Partnership Instances
    15.2     Analysis by Type of Partnership
    15.3     Analysis by Leading Players
    15.4     Analysis by Geography
16    Supplier Landscape
    16.1     Market Share by Top 5 Companies
    16.2      QIAGEN N.V.
        16.2.1    Financial Analysis
        16.2.2    Product Portfolio
        16.2.3    Demographic Reach and Achievements
        16.2.4    Mergers and Acquisitions
        16.2.5    Certifications 
    16.3      Merck KGaA
        16.3.1    Financial Analysis
        16.3.2    Product Portfolio
        16.3.3    Demographic Reach and Achievements
        16.3.4    Mergers and Acquisitions
        16.3.5    Certifications
    16.4     Tecan Trading AG 
        16.4.1    Financial Analysis
        16.4.2    Product Portfolio
        16.4.3    Demographic Reach and Achievements
        16.4.4    Mergers and Acquisitions
        16.4.5    Certifications
    16.5     Greiner Holding AG
        16.5.1     Financial Analysis
        16.5.2    Product Portfolio
        16.5.3    Demographic Reach and Achievements
        16.5.4    Mergers and Acquisitions
        16.5.5    Certifications
    16.6     Micronic 
        16.6.1    Financial Analysis
        16.6.2    Product Portfolio
        16.6.3    Demographic Reach and Achievements
        16.6.4    Mergers and Acquisitions
        16.6.5    Certifications
    16.7     BioKryo
        16.7.1    Financial Analysis
        16.7.2    Product Portfolio
        16.7.3    Demographic Reach and Achievements
        16.7.4    Mergers and Acquisitions
        16.7.5    Certifications
    16.8     SPT Labtech 
        16.8.1    Financial Analysis
        16.8.2    Product Portfolio
        16.8.3    Demographic Reach and Achievements
        16.8.4    Mergers and Acquisitions
        16.8.5    Certifications
    16.9     ASKION GmbH
        16.9.1    Financial Analysis
        16.9.2    Product Portfolio
        16.9.3    Demographic Reach and Achievements
        16.9.4    Mergers and Acquisitions
        16.9.5    Certifications
    16.10    Cell&Co BioServices 
        16.10.1    Financial Analysis
        16.10.2    Product Portfolio
        16.10.3    Demographic
        16.10.4    Mergers and Acquisitions
        16.10.5    Certifications
    16.11    CTIBiotech 
        16.11.1    Financial Analysis
        16.11.2    Product Portfolio
        16.11.3    Demographic Reach and Achievements
        16.11.4    Mergers and Acquisitions
        16.11.5    Certifications
17    Europe Biobanking Market – Distribution Model (Additional Insight)
    17.1     Overview 
    17.2     Potential Distributors 
    17.3     Key Parameters for Distribution Partner Assessment 
18    Key Opinion Leaders (KOL) Insights (Additional Insight)
19    Company Competitiveness Analysis (Additional Insight)
    19.1     Very Small Companies
    19.2     Small Companies
    19.3     Mid-Sized Companies
    19.4     Large Companies
    19.5     Very Large Companies
20    Payment Methods (Additional Insight)
    20.1     Government Funded
    20.2     Private Insurance
    20.3     Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.